

TB or not TB, that is the question

2018 WMLH State Conference Oct 10, 2018



PATIENT #1



History

- No known prior TB history.
- Foreign born, came to the US when a teenager.
- 4 week hx of cough, sputum, fevers, intermittent night sweats, and weight loss.
- Had not been on meds prior to this illness. No prior weight loss.



1/2/18 Physician outside hospital network

- RADIOLOGY FINDINGS:
 - PA and lateral views of the chest obtained on 01/02/2018 are reviewed without available comparison.
 - There is fairly extensive coarse reticular and patchy infiltrate within the right upper lobe as well as milder patchy and reticular infiltrate within the left upper lobe and right middle lobe. A small right basilar pleural effusion is present. No evidence of pneumothorax. Heart size is within normal limits.
- IMPRESSION:
 - Bilateral lung infiltrates noted, most prominent within the right upper lobe compatible with pneumonia.
- Since out of network do not know if labs were ordered



1/5/18 Clinic within hospital network

- Another chest x-ray was performed and reviewed.
 - Secondary to the area of involvement in the appearance and did question the patient if he had any exposure to her risk for tuberculosis which he denied. He states he's not any travel out of the country over the past 6 months.
 - Radiology had concerns about pneumonia and possible tuberculosis pattern on the chest xray. Recommendations were for pulmonary consult ASAP.



- Patient had a sputum culture ordered, patient declined lab work at that time.
 - Patient wanted to collect at home and submit to lab in morning
- Patient advised to avoid any respiratory interaction secondary to the concern about spreading infection
- Patient referred to pulmonologist



1/6/18

- Seen at clinic within hospital network to submit specimen:
 - Routine Sputum culture ordered at sent to other hospital lab in network to work up for suspected pneumonia
 - Reported out "Moderate Normal Flora"



Pulmonology:

- 1/8/18 Scheduled appointment with Pulmonologist – did not show up
- Patient seen by Pulmonologist 1/9/18:
 - Noticed that C AFB not ordered or sent to main micro lab in hospital network
 - Called to have sputum sent to main micro lab and have C AFB performed



1/10/18 – Micro Lab

- Sputum from 1/6/18 processed for C AFB
 - \odot Patient had Many AFB seen on Auramine O stain
 - Cepheid MTB/RIF performed
 - MTB: Detected
 - RIF: Not Detected
- Local Health Department was notified

 Orders for patient to be put on TB medications on
 1/11/18



Lab information

• 1/10/18:

Smear and MTB/RIF positive

- 1/15/18:
 - VersaTrek Myco positive with Roping AFB and Bacteria
 - Subculture: BAP, 7H11, LJ
 - Reprocessed VersaTrek 1/16/18



- 2/12/18:
 - \odot Smear of reprocessed VersaTrek Bottle
 - AFB seen
 - Subculture of VersaTrek
- 2/19/18:
 - *M. avium* growing
 - See MTB slight growth, unable to separate out from *M. avium* colonies
 - State was able to isolate out MTB from primary specimen we had sent them to perform susceptibility testing



PATIENT #2



History

- 80 Y female with left sided moderately differentiated squamous cell lung cancer (not on chemo, s/p recent radiation therapy)
- Hypothyroidism
- Osteoporosis,
- Coronary Artery Disease and Peripheral Artery Disease
- Right hip tendonitis



ED Visit 12/30/17

- Patient presents to ED after falling out of bed.
 - Patient does not recall falling and son states she has fallen 4 times in last 2 weeks
 - Patient has pain in right hip
- Patient says has had cough for last 2 years as well as increased SOB
 - Patient received Oxygen in ED and said felt an improvement
 - \circ CXR ordered



ED Visit

- New bilateral lung opacities with a superimposed infectious/inflammatory process suspected bilaterally were seen on chest x-ray.
- Patient admitted to inpatient floor for suspected pneumonia
 - Respiratory Virus NAAT: Negative
 - Blood culture: Negative
 - Legionella and S. pneumoniae urine antigens: Negative



Inpatient stay

- Patient transferred to the MICU 1/4/18 due to worsening of symptoms
 - Bronchoscopy performed 1/5/18
 - While on the floor she continued to require O2 10-15l but she remained stable with no other respiratory complaints
- Stable for transfer back to inpatient floor on 1/7/2018
- Patient discharged 1/13/18 to rehab facility

 Patient was told to follow up with a pulmonologist



Lab Results 1/5/18 BAL

- Culture respiratory/SA-MRSA NAAT:
 - Culture: 50K CFU/ML C. albicans, <10K CFU/ML MOF
 - \odot SA-MRSA NAAT: Negative for both
- Fungal culture:
 - 4+ C. albicans, 4+ C. glabrata
- Pneumocystis DFA: Negative
- Respiratory virus NAAT & Atypical Pneumonia NAAT: Negative
- AFB Culture.....



AFB Culture

- 1/6/18: No AFB Seen on concentrated smear
- Liquid media:
 - Went positive 1/16/18: Bacteria and yeast seen
 - VersaTrek bottle reprocessed 1/16/18
 - Reprocessed bottle:
 - Went positive 1/23/18: NOS, performed Blind sub and put back in instrument
 - 1/30/18 "dry" colonies seen on blind sub, Kinyoun Positive

• MALDI TOF: *M. tuberculosis*



MTB isolate

- Notified Pulmonology department 1/30/18

 Patient had missed appointment with them
 Called rehab facility to make sure patient was put in isolation, reduced prednisone, and referred patient for ID consult
- Facility ordered Quantiferon test:

 \odot Test came back negative



MTB isolate

- After reporting tech was suspicious since 2nd MTB patient within <1 month
 - On average see 2 4 new pulmonary MTB cases yearly

 $\odot~2^{nd}$ in first month of the year

 Tech did some investigating and saw patient 1 and patient 2 had liquid media reprocessed on the same day



Investigation

- Medical Director called on 1/30/18 regarding possible cross contamination
- 1/31/18 WSLH TB Lab contacted to help with investigation of possible cross contamination

 Both patient samples sent to WSLH for TB Genotyping 2/1/18



WSLH Response

- Made sure that isolates sent for TB Genotyping were processed right away
- 2/8/18 preliminary results received from WSLH

 Patient #2 isolate had similar banding pattern from
 Patient #1
 - Results suggestive of laboratory contamination
- 2/15/18 confirmation with 2nd method that isolate from Patient #1 was same as Patient #2



ID consult

- Patient did not show for appointment 2/5/18
- ID were previously notified by Medical Director regarding possible laboratory cross contamination event.
 - ID decided to wait on Genotyping results before treating patient
- 2/8/18 ID informed of laboratory contamination event



ID Consult notes from 2/8/18

- Called to inform patient that the test on the BAL showing possible MTb was a laboratory contamination event. There is no evidence she has tuberculosis.
- Left message on voice mail and gave call back numbers for the ID clinic in case she wants to discuss further.



What is TB Genotyping?

• 2 – 3 Methods involved:

○ Spoligotyping (spacer oligo typing)

- Variable number of tandem repeat (VNTR) Mycobacterial interspersed repetitive unit (MIRU) analysis
- IS6110-based restriction fragment length polymorphism (RFLP) analysis



Spoligotyping

- PCR amplification of a highly polymorphic direct repeat locus in the *M. tuberculosis* genome
- Performed on a membrane and looks at banding pattern
 - Looks for the absence (no band) or presence (dark band) of certain unique spacer sequences in this region
 - Breaks down banding pattern into a digital code
 - 43 regions looked at and broken down into a binary code
 1 for band, 0 for absence of band
 - Binary code of 43 regions broken down into a "14 + 1" code

 Binary code put in groups of 3, with 1 band extra
 - 14 + 1 code broken down into octal designation that is compared to other isolates
 - 0 4+2+1 equation (000 = 0; 001 = 1; 010 = 2; 011 = 3; 100 = 4; 101 = 5; 110 = 6; 111 = 7)



Spoligotyping example

<i>Exa</i> 1	mple	1				spa	acers						-	43	
															Original banding pattern
111	111	111	111	111	111	100	111	111	111	110	000	111	111	1	Binany code
111	-111	-111-	.111	111	111	-100	-111-	111	-111	110	-000	-111	.111	-1	14+1 grouping
7	7	7	7	7	7	4	7	7	7	6	0	7	7	1	Odal designation
<i>Exa</i>	nple	2				spa	cers							43	
Exa 1		2													Original banding pattern
													-		Original banding pattern Binany code
			0 11		111	II 011	1 100	111		∎∎ 110	000	1	000	0	Binary code



VNTR - MIRU

- VNTR Typing:
 - Based on analysis of DNA segments containing "tandem repeated" sequences
 - The number of copies of the repeated sequence varies among strains
- MIRU:
 - $\,\circ\,$ Class of tandem repeated sequences
 - Looks for the number of repeated sequences at 24 specific loci
 - Reported as a two 12 digit code



VNTR – MIRU Example

Example 1												
MIRU locus name	02	04	10	16	20	23	24	26	27	31	39	40
No. of repeats	2	3	2	2	3	4	2	5	3	3	2	2
MIRU designation 232234253322												



RFLP

• Detects variations in a specific section of the *M. tuberculosis* genome

○ Insertion element IS6110

- Method:
 - DNA is purified from *M. tuberculosis*
 - A restriction enzyme is added that cuts the DNA into hundreds of different fragments as specific sequences
 - Fragments separated by size on agarose gel and transferred to a membrane
 - Probe is used to detect fragments containing IS6110
 - Each copy of IS6110 produces one band



RFLP Example

	IS6110 RFLP patterns	No.	* Country	G
		NLA009700742 NLA009701289	0.5	Somali
_1		NLA009701389	3	S
	1 1 1 1 111	NLA009700279	2	
20 Store	THE FLE	CA-90	4 South Korea	94.
		NLA009750438	4	
	1111111	NLA009702350	1	
	1117 11 81 81	NLA009801353	2 .	
- I r		NLA009802127	3 Vietnam	
	COLUMN TI COM I	NLA009800535		Beijing
	101000000000000000000000000000000000000	NLA009801014	3	
	101101000000000000000000000000000000000	CA-20	3 Morgolia	
	THE MALE & B. L. LANS.	NLA000100560	CONTRACTOR OF A DECISION OF A DECISIONO OF A DECISION	
		NLA009802122		
	1.00.01.00	CA-111	3 South Korea	
	11111111111111111	NLA009802124		
	2/1 2 2/2 2/2	81_085	3	82
	111 1 111 111	51_066	3	
	1 8 8 108	NLA000400402	2	
	1 11 18 2218	NLA009700243		
	111 1 111 1 1	NLA009800529	CT 1 1 1	
	B1 B1 1	CA-42	3 June	
	B11 B 1 11 11	CA-7	4 Mongolia	
	1 11 1 1 1	NLA000301180		
		NLA000400647	17.2 P. C.	
	1 1 1 1 1 1 1	CA-53	3 Argentine	
		NLA009402261		I for early see
		CA-88	3 Bolivia	Haarlem
	I FRE E R	NLA000001650		
	181 18	NLA000301029	201 - C - C - C - C - C - C - C - C - C -	
-	111 11 11	CA-8	3 Vietnam	



TB Genotyping – Why Use It

- Discover unsuspected transmission relationships between TB patients
- Establish criteria for outbreak-related case definition

Identify additional persons involved in outbreak
 Determine completeness of contact investigations

- Detect laboratory cross-contamination event
- Distinguish between reactivation vs new infection



Laboratory Cross-Contamination

- CDC:
 - 2% of all *M. tuberculosis* cultures represent falsepositive results due to laboratory cross-contamination
- When to suspect false-positive result:
 - Single confirmed culture
 - \odot Clinical presentation is inconsistent with lab result
 - No clinical improvement despite adequate TB therapy



Common Causes of Cross-Contamination

- Use of common flask for reagents
- Aerosol creation or spills during processing
 - Contamination of equipment or supplies (pipettes, syringe, loops) inside BSC
 - Contamination of centrifuge carriers
- Processing of large batches
 - Breakdown in SOP practices
 - $\,\circ\,$ Lack of spacing with specimen tubes in processing racks
- Failure of BSC
- Mislabels
 - Wrong persons culture inoculated



Lessons Learned

- Investigating potential reasons for event

 Mislabel vs Cross Contamination
 Technologist was training
- Importance of Critical Thinking
 Awareness of MTB prevalence
- Importance of notification of possible event
- Importance of utilizing partners like WSLH



Questions?